Appeals court sides with Roche in Takeda row

The US Court of Appeals for the Federal Circuit has quashed an appeal from the Takeda (TYO: 4502) unit Baxalta in relation to Roche’s (ROG: SIX) hemophilia treatment Hemlibra (emicizumab).

Baxalta had claimed that the blockbuster product infringed one of its patents, saying that Hemlibra copies its patented antibodies in the way that it clots blood.

The District Court for the District of Delaware last year found that the relevant parts of Baxalta's patent were invalid, denying the company’s compensation claim and its demand that Roche stop selling Hemlibra in the USA until the patent had expired.